Challenges with surgical treatment of glaucoma are numerous and frequent, especially with the more
complicated forms such as neovascular or uveitic glaucoma. Surgeries often fail which have driven the search for using a
surgical adjunct to improve the outcomes and longevity of glaucoma procedures, while lowering their complication rates.
VEGF levels have been found to be elevated in patients with both primary open angle glaucoma and secondary
glaucomas. The use of anti-VEGF agents is now being investigated in the treatment of all types of glaucoma. The
information is early and limited, but what is known will be reviewed in this article. In considering anti-VEGF agents in
the treatment of glaucoma, some evidence suggests that anti-VEGF agents may induce glaucoma by elevating intraocular
pressure, which will also be reviewed.
Keywords: Antivascular endothelial growth factor, bevacizumab, bleb, glaucoma, intraocular pressure, mitomycin C,
neovascular glaucoma, ranibizumab, trabeculectomy, glaucoma, surgery
Rights & PermissionsPrintExport